Philogen Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Dario Neri
Chief executive officer
€378.0k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 29.8yrs |
| CEO ownership | n/a |
| Management average tenure | 29.8yrs |
| Board average tenure | no data |
Recent management updates
Recent updates
Philogen's (BIT:PHIL) Earnings Aren't As Good As They Appear
Oct 04
Late-stage Approvals Plus Sun Pharma Will Transform Oncology Despite Risks
Key Takeaways Advancing late-stage therapies and strategic pharma partnerships position Philogen for recurring product sales, stronger margins, and reduced funding risk through enhanced cash flow visibility. Alignment with personalized medicine trends and a robust cash position support long-term growth, innovation, and protection of shareholder value amid rising global demand for oncology solutions.Analyst Forecasts For Philogen S.p.A. (BIT:PHIL) Are Surging Higher
Apr 14Earnings Update: Philogen S.p.A. (BIT:PHIL) Just Reported And Analysts Are Boosting Their Estimates
Mar 31What Philogen S.p.A.'s (BIT:PHIL) P/S Is Not Telling You
Feb 24Here's Why We're Watching Philogen's (BIT:PHIL) Cash Burn Situation
Jun 03CEO
Dario Neri (62 yo)
Prof. Dr. Dario Neri, PhD co-founded Philogen S.p.A in 1996 and serves as its CSO, President of The Scientific Advisory Board and Chief Executive Officer and Managing Director. Prof. Dr. Neri served as Sc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | no data | €365.00k | no data | |
| Co-Founder | 29.8yrs | €378.00k | no data | |
| Co-Founder | no data | €227.00k | no data | |
| Chief Financial Officer | no data | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Head of Human Resources | less than a year | no data | no data | |
| Chief Medical Officer | no data | no data | no data | |
| Deputy CMO & Head of Clinical Operations | no data | no data | no data |
Experienced Management: PHIL's management team is seasoned and experienced (29.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/30 19:51 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Philogen S.p.A. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rajan Sharma | Goldman Sachs |
| Victor Floch | Stifel, Equities Research |
| Clemence Thiers | Stifel, Equities Research |